Purpose: The goal of is this study is to better understand the real world experience for the use of vedolizumab in the treatment of pediatric Crohn’s disease

Primary/ Secondary Outcomes

  • Primary Outcome: Clinical remission rates at 1 year
  • Secondary Outcome: Significant baseline factors that predict response to vedolizumab and effect on growth parameters at 1 year

Funding Source: N/A

Study Period:Aug 2020-Jan 2021

Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment at this time.

Contact: ImproveCareNow Research

Built by Veracity Media on NationBuilder